Current Report Filing (8-k)
November 25 2019 - 4:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 20, 2019
PROPHASE
LABS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0-21617
|
|
23-2577138
|
(State
or other
jurisdiction
of incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
621
N. Shady Retreat Road
Doylestown,
PA
|
|
18901
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (215) 345-0919
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of Each Exchange on Which Registered
|
Common Stock, par
value $0.0005
|
|
PRPH
|
|
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
November 20, 2019, the Compensation Committee of the board of directors of ProPhase Labs, Inc. (the “Company”) approved
a discretionary cash bonus payment to Monica Brady, the Company’s Chief Financial Officer, in the amount of $35,000, in
recognition of her contributions to the Company for fiscal year 2019. The Compensation Committee also granted Ms. Brady a stock
option to purchase 100,000 shares of the Company’s common stock at an exercise price of $2.01, the closing price of the
Company’s common stock on the date of grant. The stock option will vest in four equal annual installments beginning on the
date of grant.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ProPhase Labs, Inc.
|
|
|
|
|
By:
|
/s/
Ted Karkus
|
|
|
Ted Karkus
|
|
|
Chairman of the Board, Chief Executive Officer and
Director
|
Date:
November 25, 2019
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Sep 2023 to Sep 2024